The oral GLP-1 era got its first direct comparison. Late-June ADA data showed orforglipron, already approved for obesity, outperforming oral semaglutide on blood sugar in diabetes, with more side effects.
Late-June 2026 analyses from ADA detailed orforglipron (Foundayo), the first oral non-peptide GLP-1, already approved for obesity in April. In the ACHIEVE-3 trial, the first head-to-head of two oral GLP-1s, orforglipron was superior to oral semaglutide on blood-sugar reduction in type 2 diabetes, though with more gastrointestinal side effects and discontinuations.
Two oral GLP-1 pills are now on the market, and for the first time, they went head-to-head.
Late-June ADA analyses detailed the comparison, and what it means.
Following the ADA Scientific Sessions, late-June 2026 analyses detailed the ACHIEVE program for orforglipron (Foundayo, Eli Lilly), the first oral small-molecule (non-peptide) GLP-1, which can be taken any time of day without food or water restrictions and was approved for weight management in April 2026. In type 2 diabetes, ACHIEVE-2 showed superiority to dapagliflozin, and ACHIEVE-5 showed benefit added to insulin. The most notable, ACHIEVE-3, was the first head-to-head between the two clinically available oral GLP-1s: over 52 weeks, both orforglipron doses produced superior blood-sugar (HbA1c) reductions versus oral semaglutide, with commentary describing orforglipron as potentially the most efficacious oral antihyperglycemic option, though gastrointestinal side effects and treatment discontinuations were more common. Several trials were simultaneously published in major journals.
One important limitation: unlike oral semaglutide, which has cardiovascular outcomes data, orforglipron has not yet completed a cardiovascular outcomes trial. In diabetes, orforglipron remains investigational (it is approved for obesity).
For consumers, an effective, any-time oral GLP-1 lowers practical barriers, no needles, no rigid dosing routine, which may aid adherence and broaden primary-care access. But head-to-head superiority on blood sugar came with more GI side effects, and the absence of cardiovascular outcomes data is a real consideration for higher-risk patients. As always, trial results are averages, and the right choice is individualized with a prescriber.
Watch for orforgliprons cardiovascular outcomes data and any diabetes indication, plus how pricing and access shape real-world use (it launched for obesity at $149 per month for self-pay patients). For individuals, the practical step is to discuss whether an oral GLP-1 fits their goals and health profile with a prescriber, and to obtain any medication as the FDA-approved product from a legitimate pharmacy.